Trials / Completed
CompletedNCT00302653
Rasburicase in Tumor Lysis Syndrome
Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasburicase | Rasburicase 0,20mg/Kg/Day once a day 3-7 days |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2006-11-01
- First posted
- 2006-03-14
- Last updated
- 2009-09-25
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00302653. Inclusion in this directory is not an endorsement.